NAVB - Navidea Biopharmaceuticals, Inc

NYSE American - NYSE American Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/2015
Total Revenue1,810.4374,971.6343,013.361
Cost of Revenue3.65162.263.226
Gross Profit1,806.7864,909.3743,010.135
Operating Expenses
Research Development4,513.8427,138.0810,562.729
Selling General and Administrative11,169.9517,920.03610,888.146
Non Recurring---
Others---
Total Operating Expenses---
Operating Income or Loss-13,877.007-10,148.742-18,440.74
Income from Continuing Operations
Total Other Income/Expenses Net-4,081.652,790.873-3,028.688
Earnings Before Interest and Taxes-17,789.686-7,377.894-23,044.597
Interest Expense---
Income Before Tax-17,789.686-7,377.894-23,044.597
Income Tax Expense-4,062.489--
Minority Interest668.7468.91469.558
Net Income From Continuing Ops-13,727.197-7,377.894-23,044.597
Non-recurring Events
Discontinued Operations88,673.053-6,931.137-4,518.938
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income74,945.856-14,309.031-27,563.535
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares74,946.066-14,308.383-27,608.68